Roche

Few pharmaceuticals players in Europe match the executional depth of Roche. From Basel, the group manages a workforce of approximately 103k and generates close to $71B in revenue, while steadily widening the gap with regional peers.

Recent strategic moves point to a deliberate pivot toward higher-margin segments, where pricing power and brand equity matter more than pure volume.

“Roche is, in its category, exactly the kind of compounding regional champion the next decade of capital allocation will reward.”

The outlook remains constructive: order books, hiring patterns and capex guidance all point to a multi-year expansion phase.